Clinical Trial Update: Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine [Phase 2]

View source ↗

Summary

This document reports a Phase 2 clinical trial update evaluating the immunogenicity, efficacy and safety of the MSP3-LSP malaria vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• MSP3-LSP malaria vaccine (MSP3-LSP)

Snippet

Sponsor: African Malaria Network Trust | Conditions: Malaria | Phase 2 | Status: UNKNOWN